VistaGen Therapeutics Net Income Over Time
| VTGN Stock | USD 0.55 0.04 7.84% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out VistaGen Therapeutics Performance and VistaGen Therapeutics Correlation. Will Biotechnology sector continue expanding? Could VistaGen diversify its offerings? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every VistaGen Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.92) | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets | Return On Equity |
Investors evaluate VistaGen Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating VistaGen Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause VistaGen Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, VistaGen Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare VistaGen Therapeutics and related stocks such as Spero Therapeutics, Seer Inc, and Seres Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
| SEER | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (6.3 M) | (16 M) | (32.8 M) | (71.2 M) | (93 M) | (86.3 M) | (86.6 M) | (77.9 M) | (81.8 M) |
| MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (113.7 M) | 136 K | 122.4 K | 128.5 K |
| IRD | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (24.6 M) | (56.7 M) | 17.9 M | (10 M) | (57.5 M) | (51.8 M) | (49.2 M) |
| CGTX | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (10.1 M) | (11.7 M) | 757 K | (25.8 M) | (34 M) | (30.6 M) | (29 M) |
| HURA | (5.6 K) | (18.9 K) | (8.3 M) | (8.3 M) | (4.3 M) | (8.9 M) | (8.1 M) | (11.1 M) | (8 M) | (9.1 M) | (38.3 M) | (7 M) | (9.4 M) | (29.3 M) | (21.7 M) | (19.5 M) | (18.5 M) |
| AGEN | (18.1 M) | (23.3 M) | (11.3 M) | (30.1 M) | (42.5 M) | (87.9 M) | (127 M) | (120.7 M) | (159.7 M) | (107.7 M) | (180.9 M) | (23.9 M) | (220.1 M) | (245.8 M) | (227.2 M) | (204.5 M) | (194.3 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (24.7 M) | (27.3 M) | (24.6 M) | (25.8 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (100.6 M) | (42.9 M) | (52.4 M) | (102.3 M) | (92.1 M) | (87.5 M) |
| INO | (6.6 M) | (15.3 M) | (19.7 M) | (66 M) | (36.1 M) | (29.2 M) | (73.7 M) | (88.2 M) | (97 M) | (119.4 M) | (166.4 M) | (303.7 M) | (279.8 M) | (135.1 M) | (107.3 M) | (96.5 M) | (101.4 M) |
VistaGen Therapeutics and related stocks such as Spero Therapeutics, Seer Inc, and Seres Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in VistaGen Therapeutics financial statement analysis. It represents the amount of money remaining after all of VistaGen Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| VistaGen Therapeutics | VTGN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 343 Allerton Avenue, |
| Exchange | NASDAQ Exchange |
USD 0.55
Check out VistaGen Therapeutics Performance and VistaGen Therapeutics Correlation. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
VistaGen Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.